
    
      The study's objective is to evaluate the role of rTMS for symptom reduction of spasticity
      among patients with upper motor neuron predominant motor neuron disease. This study is
      12-week open label safety and efficacy trial. A total of 10 subjects with PLS and UMN/ MND
      will be enrolled in this study.
    
  